Predicted protein targets (top 20)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | STS | P08842 | 2/20 | 0.69 |
| ▸ | HSD17B1 | P14061 | 6/20 | 0.57 |
| ▸ | ESR1 | P03372 | 4/20 | 0.57 |
| ▸ | ESR2 | Q92731 | 3/20 | 0.57 |
| ▸ | LMNA | P02545 | 2/20 | 0.57 |
| ▸ | MAPT | P10636 | 2/20 | 0.57 |
| ▸ | HIF1A | Q16665 | 2/20 | 0.57 |
| ▸ | SHBG | P04278 | 2/20 | 0.57 |
| ▸ | AKR1B10 | O60218 | 1/20 | 0.57 |
| ▸ | CYP1A2 | P05177 | 1/20 | 0.57 |
| ▸ | PGR | P06401 | 1/20 | 0.57 |
| ▸ | SERPINA6 | P08185 | 1/20 | 0.57 |
| ▸ | CYP3A4 | P08684 | 1/20 | 0.57 |
| ▸ | AR | P10275 | 1/20 | 0.57 |
| ▸ | CYP19A1 | P11511 | 1/20 | 0.57 |
| ▸ | AKR1B1 | P15121 | 1/20 | 0.57 |
| ▸ | NFKB1 | P19838 | 1/20 | 0.57 |
| ▸ | SLC6A4 | P31645 | 1/20 | 0.57 |
| ▸ | OPRM1 | P35372 | 1/20 | 0.57 |
| ▸ | SNCA | P37840 | 1/20 | 0.57 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL4893106 | 1.00 | STS (0.69) | STSHSD17B1ESR1ESR2LMNA | |
| SCHEMBL217081 | 0.94 | STS (0.62) | STSHSD17B1ESR1ESR2LMNA | |
| SCHEMBL218464 | 0.94 | STS (0.62) | STSHSD17B1ESR1ESR2LMNA | |
| SCHEMBL217082 | 0.94 | STS (0.62) | STSHSD17B1ESR1ESR2LMNA | |
| SCHEMBL18652154 | 0.94 | STS (0.62) | STSHSD17B1ESR1ESR2LMNA | |
| SCHEMBL218463 | 0.94 | STS (0.62) | STSHSD17B1ESR1ESR2LMNA | |
| SCHEMBL2738481 | 0.94 | STS (0.62) | STSHSD17B1ESR1ESR2LMNA | |
| SCHEMBL5025212 | 0.92 | STS (0.60) | STSHSD17B1ESR1ESR2LMNA | |
| SCHEMBL5025218 | 0.92 | STS (0.60) | STSHSD17B1ESR1ESR2LMNA | |
| SCHEMBL22089284 | 0.92 | STS (0.59) | STSHSD17B1ESR1ESR2LMNA |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 27 patents — showing the first 20. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| EP-3634975-B1 | 17-OXIMES OF 15.BETA.-[3-PROPANAMIDO]-SUBSTITUTED ESTRA-1,3,5(10)-TRIEN-17-ONES FOR USE IN INHIBITION OF 17.BETA.-HYDROXYSTEROID DEHYDROGENASES | ORGANON R&D FINLAND LTD (FI) | 2024-02-28 | — | — | EP | disclosed |
| US-20220127303-A1 | THERAPEUTICALLY ACTIVE STEROIDAL DERIVATIVES | FORENDO PHARMA LTD (FI) | 2022-04-28 | — | — | US | disclosed |
| US-11254703-B2 | Therapeutically active steroidal derivatives | FORENDO PHARMA LTD (FI) | 2022-02-22 | — | — | US | disclosed |
| US-20200317718-A1 | THERAPEUTICALLY ACTIVE STEROIDAL DERIVATIVES | FORENDO PHARMA LTD (FI) | 2020-10-08 | — | — | US | disclosed |
| WO-2020115371-A1 | ESTRA-1,3,5(10)-TRIENE COMPOUNDS CONDENSED IN POSITION 16(17) WITH A PYRAZOLE RING AS INHIBITORS OF 17-HSD1 | FORENDO PHARMA LTD (FI) | 2020-06-11 | — | — | WO | disclosed |
| US-10626140-B2 | Prodrugs of 17β-HSD1-inhibitors | FORENDO PHARMA LTD (FI) | 2020-04-21 | — | — | US | disclosed |
| EP-3013845-B1 | THERAPEUTICALLY ACTIVE ESTRATRIENTHIAZOLE DERIVATIVES AS INHIBITORS OF 17B-HYDROXYSTEROID DEHYDROGENASE, TYPE 1 | FORENDO PHARMA LTD (FI) | 2020-03-18 | — | — | EP | disclosed |
| US-10413557-B2 | Prodrugs of 17.BETA.-HSD1-inhibitors | FORENDO PHARMA LTD. (FI) | 2019-09-17 | — | — | US | disclosed |
| US-10377791-B2 | Therapeutically active estratrienthiazole derivatives as inhibitors of 17 B-hydroxysteroid dehydrogenase, type 1 | FORENDO PHARMA LTD. (FI) | 2019-08-13 | — | — | US | disclosed |
| US-9850272-B2 | Therapeutically active estratrienthiazole derivatives as inhibitors of 17.beta-hydroxy-steroid dehydrogenase, type 1 | FORENDO PHARMA LTD. (FI) | 2017-12-26 | — | — | US | disclosed |
| US-20170114090-A1 | THERAPEUTICALLY ACTIVE ESTRATRIENTHIAZOLE DERIVATIVES AS HINIBITORS OF 17 B-HYDROXYSTEROID DEHYDROGENASE, TYPE 1 | FORENDO PHARMA LTD (FI) | 2017-04-27 | — | — | US | disclosed |
| US-20170081356-A1 | THERAPEUTICALLY ACTIVE ESTRATRIENTHIAZOLE DERIVATIVES AS INHIBITORS OF 17.BETA-HYDROXY-STEROID DEHYDROGENASE, TYPE 1 | FORENDO PHARMA LTD (FI) | 2017-03-23 | — | — | US | disclosed |
| US-20170081356-A1 | THERAPEUTICALLY ACTIVE ESTRATRIENTHIAZOLE DERIVATIVES AS INHIBITORS OF 17.BETA-HYDROXY-STEROID DEHYDROGENASE, TYPE 1 | FORENDO PHARMA LTD (FI) | 2017-03-23 | — | — | US | disclosed |
| US-20170081357-A1 | THERAPEUTICALLY ACTIVE 17-NITROGEN SUBSTITUTED ESTRATREINTHIAZOLE DERIVATIVES AS INHIBITORS OF 17.BETA-HYDROXYSTEROID DEHYDROGENASE | FORENDO PHARMA LTD (FI) | 2017-03-23 | — | — | US | disclosed |
| US-20170081357-A1 | THERAPEUTICALLY ACTIVE 17-NITROGEN SUBSTITUTED ESTRATREINTHIAZOLE DERIVATIVES AS INHIBITORS OF 17.BETA-HYDROXYSTEROID DEHYDROGENASE | FORENDO PHARMA LTD (FI) | 2017-03-23 | — | — | US | disclosed |
| WO-2014207311-A1 | THERAPEUTICALLY ACTIVE ESTRATRIENTHIAZOLE DERIVATIVES AS INHIBITORS OF 17.BETA.-HYDROXY-STEROID DEHYDROGENASE, TYPE 1 | FORENDO PHARMA LTD (FI) | 2014-12-31 | — | — | WO | disclosed |
| WO-2014207309-A1 | THERAPEUTICALLY ACTIVE ESTRATRIENTHIAZOLE DERIVATIVES AS INHIBITORS OF 17 B-HYDROXYSTEROID DEHYDROGENASE, TYPE 1 | FORENDO PHARMA LTD (FI) | 2014-12-31 | — | — | WO | disclosed |
| WO-2014207310-A1 | THERAPEUTICALLY ACTIVE 17-NITROGEN SUBSTITUTED ESTRATRIENTHIAZOLE DERIVATIVES AS INHIBITORS OF 17.BETA.-HYDROXYSTEROID DEHYDROGENASE | FORENDO PHARMA LTD (FI) | 2014-12-31 | — | — | WO | disclosed |
| US-8288367-B2 | Treatment or inhibition of a steroid hormone dependent disorder; reducing spermatogenesis or male virility; 17 beta -hydroxysteroid dehydrogenase (17 beta-HSD) inhibitors; compounds such as 3-(benzylamino)-15alpha-(4-morpholin-4-yl-4-oxobutyl)estra-1(10),2,4-trien-17-one | SOLVAY PHARMACEUTICALS GMBH (DE) | 2012-10-16 | — | — | US | disclosed |
| US-20080255075-A1 | SUBSTITUTED ESTRATRIENE DERIVATIVES AS 17BETA HSD INHIBITORS | SOLVAY PHARMACEUTICALS GMBH (DE) | 2008-10-16 | — | — | US | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (10 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20080255075-A1 | SUBSTITUTED ESTRATRIENE DERIVATIVES AS 17BETA HSD INHIBITORS | HSD17B11, HSD17B1, HSD17B2 | STS 33/4885HSD17B1 2/4885ESR1 113/4885 |
| US-10413557-B2 | Prodrugs of 17.BETA.-HSD1-inhibitors | HSD17B11, HSD17B1, HSD17B7 | STS 53/4885HSD17B1 2/4885ESR1 68/4885 |
| US-20170081357-A1 | THERAPEUTICALLY ACTIVE 17-NITROGEN SUBSTITUTED ESTRATREINTHIAZOLE DERIVATIVES AS INHIBITORS OF 17.BETA-HYDROXYSTEROID DEHYDROGENASE | HSD17B11, HSD17B1, HSD17B3 | STS 26/4885HSD17B1 2/4885ESR1 51/4885 |
| US-20220127303-A1 | THERAPEUTICALLY ACTIVE STEROIDAL DERIVATIVES | HSD17B11, NR5A1, CYP17A1 | STS 39/4885HSD17B1 4/4885ESR1 46/4885 |
| US-10626140-B2 | Prodrugs of 17β-HSD1-inhibitors | HSD17B11, HSD17B1, CYP17A1 | STS 70/4885HSD17B1 2/4885ESR1 35/4885 |
| US-11254703-B2 | Therapeutically active steroidal derivatives | HSD17B11, NR5A1, CYP17A1 | STS 38/4885HSD17B1 4/4885ESR1 42/4885 |
| US-10377791-B2 | Therapeutically active estratrienthiazole derivatives as inhibitors of 17 B-hydroxysteroid dehydrogenase, type 1 | HSD17B1, HSD17B11, HSD17B3 | STS 43/4885HSD17B1 1/4885ESR1 72/4885 |
| US-20200317718-A1 | THERAPEUTICALLY ACTIVE STEROIDAL DERIVATIVES | HSD17B11, NR5A1, CYP17A1 | STS 38/4885HSD17B1 4/4885ESR1 42/4885 |
| US-20170081356-A1 | THERAPEUTICALLY ACTIVE ESTRATRIENTHIAZOLE DERIVATIVES AS INHIBITORS OF 17.BETA-HYDROXY-STEROID DEHYDROGENASE, TYPE 1 | HSD17B11, HSD17B1, HSD17B3 | STS 32/4885HSD17B1 2/4885ESR1 64/4885 |
| US-20170114090-A1 | THERAPEUTICALLY ACTIVE ESTRATRIENTHIAZOLE DERIVATIVES AS HINIBITORS OF 17 B-HYDROXYSTEROID DEHYDROGENASE, TYPE 1 | HSD17B1, HSD17B11, HSD17B3 | STS 39/4885HSD17B1 1/4885ESR1 82/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.